AstraZeneca PLC (AZN): net debt to ebitda, 10 filed years
Net debt/EBITDA at AstraZeneca PLC was 2.60x in FY2022, the newest year it could be computed. Across the 5 computed years from FY2018 it ranged from 1.59x (FY2020) to 3.35x (FY2021), with a median of 2.10x.
Tonight's figure on the company page: n/a, recomputed 2026-10-15. The table is each filed year on its own terms, with the formula below; the current figure may use trailing twelve months or, where the explainer says so, a different denominator.
Year by year
| Fiscal year | Net debt/EBITDA | Read from |
|---|---|---|
| FY2016 The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read. | n/a | 20-F, filed 2018-03-06 |
| FY2017 The filed borrowings do not add up to a total we can stand behind: the filer's own liability subtotals leave room for debt we did not read. | n/a | 20-F, filed 2018-03-06 |
| FY2018 | 2.10x | 20-F, filed 2019-03-05 |
| FY2019 | 2.02x | 20-F, filed 2020-03-03 |
| FY2020 | 1.59x | 20-F, filed 2021-02-16 |
| FY2021 | 3.35x | 20-F, filed 2022-02-22 |
| FY2022 | 2.60x | 20-F, filed 2023-02-21 |
| FY2023 No EBITDA line, and no EBITDA ratio, is filed for this year. | n/a | 20-F, filed 2024-02-20 |
| FY2024 No EBITDA line, and no EBITDA ratio, is filed for this year. | n/a | 20-F, filed 2025-02-18 |
| FY2025 No EBITDA line, and no EBITDA ratio, is filed for this year. | n/a | 20-F, filed 2026-02-24 |
How each year is computed
(Total debt - cash) / EBITDA
Each year is a ratio of lines in that year's filed annual report, with the nightly recompute's own rules for what counts as a filed line. Nothing is estimated, smoothed or filled in: a year that cannot be computed says why.
Read further
A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.